Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology

Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology

Abstract Introduction A chemogenomic set of small molecules with annotated activities and implicated roles in Alzheimer's disease (AD) called the AD Informer Set was recently developed and made available to the AD research community: https://treatad.org/data‐tools/ad‐informer‐set/. Methods Smal...

Full description

Saved in:
Bibliographic Details
Main Authors: Frances M. Potjewyd, Joel K. Annor‐Gyamfi, Jeffrey Aubé, Shaoyou Chu, Ivie L. Conlon, Kevin J. Frankowski, Shiva K. R. Guduru, Brian P. Hardy, Megan D. Hopkins, Chizuru Kinoshita, Dmitri B. Kireev, Emily R. Mason, Charles T. Moerk, Felix Nwogbo, Kenneth H. Pearce Jr., Timothy I. Richardson, David A. Rogers, Disha M. Soni, Michael Stashko, Xiaodong Wang, Carrow Wells, Timothy M. Willson, Stephen V. Frye, Jessica E. Young, Alison D. Axtman
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
AD Informer Set
Alzheimer's disease
chemogenomic set
chemogenomics
target validation
Target Enablement to Accelerate Therapy Development for Alzheimer's Disease
Online Access:https://doi.org/10.1002/trc2.12253
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/trc2.12253

Similar Items